Feasibility of Automated Insulin Delivery Guided by Continuous Glucose Monitoring in preterm infants
Archives of Disease in Childhood
BMJ Publishing Group
MetadataShow full item record
Beardsall, K., Thomson, L., Elleri, D., Dunger, D., & Hovorka, R. (2020). Feasibility of Automated Insulin Delivery Guided by Continuous Glucose Monitoring in preterm infants. Archives of Disease in Childhood, 105 (3), F279-F284. https://doi.org/10.1136/archdischild-2019-316871
Abstract: Objective: Closed-loop systems have been used to optimise insulin delivery in children with diabetes, but they have not been tested in neonatal intensive care. Extremely preterm infants are prone to hyperglycaemia and hypoglycaemia; both of which have been associated with adverse outcomes. Insulin sensitivity is notoriously variable in these babies and glucose control is time-consuming, with management requiring frequent changes of dextrose-containing fluids and careful monitoring of insulin treatment. We aimed to evaluate the feasibility of closed-loop management of glucose control in these infants. Design and Setting: Single centre feasibility study with a randomized parallel design in a neonatal intensive care unit. Eligibility criteria included birth weight <1200g and <48hours of age. All infants had subcutaneous continuous glucose monitoring for the first week of life, with those in the intervention group receiving closed-loop insulin delivery in a pre-specified window, between 48 and 72hours of age during which time the primary outcome was percentage of time in target (sensor glucose 4-8mmol/l). Results: The mean (SD) gestational age and birth weight of intervention and control study arms were 27.0(2.4) weeks, 962(164) g and 27.5(2.8) weeks, 823(282) g respectively, and were not significantly different. The time in target was dramatically increased from median (IQR) 26%(6, 64) with paper guidance to 91%(78, 99) during closed loop (p<0.001). There were no serious adverse events and no difference in total insulin infused. Conclusions: Closed-loop glucose control based on subcutaneous glucose measurements appears feasible as a potential method of optimizing glucose control in extremely preterm infants.
Funding was provided by the Evelyn Trust, the National Institute of Health Research EME Program and the National Institute of Health Research Cambridge Biomedical Research Centre. Medtronic provided the continuous glucose monitoring system and sensors. Medtronic had no role in design of the study, the gathering of data, access to data, preparation of the manuscript or decision to publish the results.
Evelyn Trust (unknown)
European Research Council (310785)
NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) (EME/11/133/07)
Cambridge University Hospitals NHS Foundation Trust (CUH) (146281)
External DOI: https://doi.org/10.1136/archdischild-2019-316871
This record's URL: https://www.repository.cam.ac.uk/handle/1810/294532
All rights reserved, Attribution 4.0 International
Licence URL: http://creativecommons.org/licenses/by/4.0/